Journal of Clinical Endocrinology & Metabolism, Vol 74, 223-225, Copyright © 1992 by Endocrine Society

ARTICLES

Massive amounts of immunoreactive endothelin in human seminal fluid

ML Casey, W Byrd and PC MacDonald
Cecil H. and Ida Green Center for Reproductive Biology Sciences, Dallas, Texas.

We found that immunoreactive endothelin (ET) is present in seminal fluid in very large amounts (500-5000 ng/L; quantification based on ET- 1 standard). This immunoreactive ET was detected by use of a radioimmunoassay system in which the N-terminal portion of ET-1 and ET- 2 (and big ET-1 and big ET-2) are recognized. Thus, the immunoreactive ET in seminal fluid may include the precursors of ET-1 or ET-2 (i.e., big ET) as well as metabolites of ET-1 or ET-2 in which the N-terminal region is intact. The levels of immunoreactive ET in seminal fluid from men with normal semen analyses and that in seminal fluid of vasectomized men were within the same range. Using a different radioimmunoassay system in which the C-terminal portion of ET-1, ET-2, and ET-3 is recognized, we found that the levels of immunoreactive ET were much lower (or undetectable). We speculate that bioactive ET may be produced and act to promote sperm transport in the male reproductive tract; thereafter, bioactive ET may be metabolized by membrane metalloendopeptidase (which is present in male reproductive tissues and semen) to immunoreactive, inactive products. Alternatively, big ET in seminal fluid may be processed in tissues of the female internal genitalia to bioactive ET, which could act to promote sperm transport through the uterine cavity by stimulating myometrial contractions.

This article has been cited by other articles:

				M J Grimshaw Endothelins and hypoxia-inducible factor in cancer Endocr. Relat. Cancer, June 1, 2007; 14(2): 233 - 244. [Abstract] [Full Text] [PDF]

				G. A. Clines, K. S. Mohammad, Y. Bao, O. W. Stephens, L. J. Suva, J. D. Shaughnessy Jr., J. W. Fox, J. M. Chirgwin, and T. A. Guise Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation Mol. Endocrinol., February 1, 2007; 21(2): 486 - 498. [Abstract] [Full Text] [PDF]

				B. A. Zonnenberg, G. Groenewegen, T. J. Janus, T. W. Leahy, R. A. Humerickhouse, J. D. Isaacson, R. A. Carr, and E. Voest Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan: An Endothelin Receptor Antagonist for Refractory Prostate Cancer Clin. Cancer Res., August 1, 2003; 9(8): 2965 - 2972. [Abstract] [Full Text] [PDF]

				A. Peri, G. Fantoni, S. Granchi, G. B. Vannelli, T. Barni, S. Amerini, C. Pupilli, G. Barbagli, G. Forti, M. Serio, et al. Gene Expression of Endothelin-1, Endothelin-Converting Enzyme-1, and Endothelin Receptors in Human Epididymis J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3797 - 3806. [Abstract] [Full Text] [PDF]

				E. S. Grant, T. Brown, A. Roach, B. C. Williams, and F. K. Habib In Vitro Expression of Endothelin-1 (ET-1) and the ETA and ETB ET Receptors by the Prostatic Epithelium and Stroma J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 508 - 513. [Abstract] [Full Text] [PDF]